Search research articles
Contact Us
Filters
Showing results (21-30 of 318) with videos related to
Page
of 32
Sort By:
Journal of Hepatology
|
November 3, 2022
NASH cirrhosis trials and major adverse liver outcomes: Big data needed
Mazen Noureddin, Stephen A Harrison
The New England Journal of Medicine
|
May 1, 2024
A Phase 3 Trial of Resmetirom in NASH with Liver Fibrosis. Reply
Stephen A Harrison, Rebecca Taub
Alimentary Pharmacology & Therapeutics
|
November 21, 2023
Editorial: Liver hypercortisolism as a potential target for MASH treatment
Stephen A Harrison, Julie Dubourg
Gastroenterology & Hepatology
|
August 31, 2012
Hepatitis C virus infection and nonalcoholic steatohepatitis
Anish Patel, Stephen A Harrison
Journal of Clinical Gastroenterology
|
August 19, 2006
Nonalcoholic fatty liver disease presenting with an isolated elevated alkaline phosphatase
Matthew W Pantsari, Stephen A Harrison
Current Gastroenterology Reports
|
February 11, 2005
Comparison of the natural history of alcoholic and nonalcoholic fatty liver disease
Shane J Mills, Stephen A Harrison
The American Journal of Gastroenterology
|
November 11, 2005
New advances in evaluation and management of patients with polycystic liver disease
Hays L Arnold, Stephen A Harrison
Journal of Hepatology
|
February 20, 2003
Hereditary hemochromatosis: update for 2003
Stephen A Harrison, Bruce R Bacon
Nature Reviews. Gastroenterology & Hepatology
|
July 31, 2013
NAFLD: Predictive value of ALT levels for NASH and advanced fibrosis
Dawn M Torres, Stephen A Harrison
Gastroenterology & Hepatology
|
March 21, 2017
Nonalcoholic Steatohepatitis: Clinical Presentation, Diagnosis, and Treatment
Joel Z Stengel, Stephen A Harrison
Page
of 32
Search research articles
Search
Showing results (21-30 of 318) with videos related to
Sort By:
Page
of 32
Journal of Hepatology
|
November 3, 2022
NASH cirrhosis trials and major adverse liver outcomes: Big data needed
Mazen Noureddin, Stephen A Harrison
The New England Journal of Medicine
|
May 1, 2024
A Phase 3 Trial of Resmetirom in NASH with Liver Fibrosis. Reply
Stephen A Harrison, Rebecca Taub
Alimentary Pharmacology & Therapeutics
|
November 21, 2023
Editorial: Liver hypercortisolism as a potential target for MASH treatment
Stephen A Harrison, Julie Dubourg
Gastroenterology & Hepatology
|
August 31, 2012
Hepatitis C virus infection and nonalcoholic steatohepatitis
Anish Patel, Stephen A Harrison
Journal of Clinical Gastroenterology
|
August 19, 2006
Nonalcoholic fatty liver disease presenting with an isolated elevated alkaline phosphatase
Matthew W Pantsari, Stephen A Harrison
Current Gastroenterology Reports
|
February 11, 2005
Comparison of the natural history of alcoholic and nonalcoholic fatty liver disease
Shane J Mills, Stephen A Harrison
The American Journal of Gastroenterology
|
November 11, 2005
New advances in evaluation and management of patients with polycystic liver disease
Hays L Arnold, Stephen A Harrison
Journal of Hepatology
|
February 20, 2003
Hereditary hemochromatosis: update for 2003
Stephen A Harrison, Bruce R Bacon
Nature Reviews. Gastroenterology & Hepatology
|
July 31, 2013
NAFLD: Predictive value of ALT levels for NASH and advanced fibrosis
Dawn M Torres, Stephen A Harrison
Gastroenterology & Hepatology
|
March 21, 2017
Nonalcoholic Steatohepatitis: Clinical Presentation, Diagnosis, and Treatment
Joel Z Stengel, Stephen A Harrison
Page
of 32